Royalty Pharma's EBIT per Share for the
three
months ended in Dec. 2023 was $1.28.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.13.
During the past 12 months, the average EBIT per Share Growth Rate of Royalty Pharma was 17.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -17.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -16.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Royalty Pharma's EBIT per Share or its related term are showing as below:
RPRX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -34.2 Med: -10.6 Max: 18.6
Current: -17.6
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Royalty Pharma was 18.60% per year. The lowest was -34.20% per year. And the median was -10.60% per year.
RPRX's 3-Year EBIT Growth Rate is ranked worse than 73.07% of 1307
companies
in the Biotechnology industry
Industry Median: 3.4
vs RPRX: -17.60
Royalty Pharma's EBIT for the
three
months ended in Dec. 2023 was $765 Mil.
Royalty Pharma EBIT per Share Historical Data
The historical data trend for Royalty Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (NAS:RPRX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Royalty Pharma EBIT per Share Related Terms
Thank you for viewing the detailed overview of Royalty Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Royalty Pharma (Royalty Pharma) Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RPRX has been successfully added to your 